Healthcare provider profile · identity verified

Ling Xu

Internal Medicine · OAKLAND, CA · NPI 1316365422

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	676	271
Amlodipine Besylate	Amlodipine Besylate	386	157
Levothyroxine Sodium	Levothyroxine Sodium	341	122
Rosuvastatin Calcium	Rosuvastatin Calcium	337	135
Lisinopril	Lisinopril	328	137
Losartan Potassium	Losartan Potassium	305	118
Omeprazole	Omeprazole	243	112
Atenolol	Atenolol	239	86
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	217	48
Albuterol Sulfate Hfa	Albuterol Sulfate	203	97
Gabapentin	Gabapentin	181	72
Metformin Hcl	Metformin Hcl	154	67
Potassium Chloride	Potassium Chloride	150	58
Alendronate Sodium	Alendronate Sodium	145	57
Simvastatin	Simvastatin	136	47
Glipizide	Glipizide	135	55
Tramadol Hcl	Tramadol Hcl	131	33
Meloxicam	Meloxicam	130	63
Hydrochlorothiazide	Hydrochlorothiazide	128	50
Metformin Hcl Er	Metformin Hcl	125	48
Ozempic	Semaglutide	120	29
Pantoprazole Sodium	Pantoprazole Sodium	118	55
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	116	45
Furosemide	Furosemide	105	48
Metoprolol Tartrate	Metoprolol Tartrate	98	39
Tamsulosin Hcl	Tamsulosin Hcl	85	42
Trazodone Hcl	Trazodone Hcl	83	42
Triamcinolone Acetonide	Triamcinolone Acetonide	80	46
Pradaxa	Dabigatran Etexilate Mesylate	74	29
Prednisone	Prednisone	74	57
Jardiance	Empagliflozin	71	30
Spiriva Respimat	Tiotropium Bromide	69	20
Wixela Inhub	Fluticasone Propion/Salmeterol	68	33
Mirtazapine	Mirtazapine	65	33
Bisoprolol Fumarate	Bisoprolol Fumarate	57	32
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	52	17
Fluoxetine Hcl	Fluoxetine Hcl	51	18
Humulin N	Insulin Nph Human Isophane	50	22
Montelukast Sodium	Montelukast Sodium	50	21
Carvedilol	Carvedilol	48	20
Allopurinol	Allopurinol	47	22
Cephalexin	Cephalexin	45	32
Hydralazine Hcl	Hydralazine Hcl	45	23
Ibuprofen	Ibuprofen	45	30
Terazosin Hcl	Terazosin Hcl	45	21
Lidocaine	Lidocaine	41	22
Estradiol	Estradiol	38	25
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	37	37
Hydrocortisone	Hydrocortisone	37	28
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	37	suppressed
Propranolol Hcl	Propranolol Hcl	37	13
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	35	14
Eliquis	Apixaban	34	12
Acyclovir	Acyclovir	33	18
Alprazolam	Alprazolam	30	suppressed
Bupropion Hcl Sr	Bupropion Hcl	30	suppressed
Buspirone Hcl	Buspirone Hcl	30	suppressed
Famotidine	Famotidine	30	15
Clopidogrel	Clopidogrel Bisulfate	28	12
Ezetimibe	Ezetimibe	28	12
Naloxone Hcl	Naloxone Hcl	28	26
Nystatin	Nystatin	28	14
Ondansetron Odt	Ondansetron	28	14
Pioglitazone Hcl	Pioglitazone Hcl	27	suppressed
Pravastatin Sodium	Pravastatin Sodium	27	suppressed
Trospium Chloride	Trospium Chloride	27	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	26	suppressed
Clonazepam	Clonazepam	24	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	24	15
Citalopram Hbr	Citalopram Hydrobromide	23	suppressed
Morphine Sulfate Er	Morphine Sulfate	23	suppressed
Mupirocin	Mupirocin	23	18
Spironolactone	Spironolactone	23	suppressed
Azelastine Hcl	Azelastine Hcl	22	suppressed
Colchicine	Colchicine	22	suppressed
Lovastatin	Lovastatin	22	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	21	suppressed
Baclofen	Baclofen	21	suppressed
Nitroglycerin	Nitroglycerin	21	12
Ondansetron Hcl	Ondansetron Hcl	21	suppressed
Tizanidine Hcl	Tizanidine Hcl	21	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	20	19
Ciclopirox	Ciclopirox	20	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	20	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	20	12
Diltiazem Hcl	Diltiazem Hcl	19	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	19	suppressed
Liraglutide	Liraglutide	19	suppressed
Alvesco	Ciclesonide	18	12
Venlafaxine Hcl Er	Venlafaxine Hcl	18	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	17	suppressed
Finasteride	Finasteride	17	suppressed
Glipizide Er	Glipizide	17	suppressed
Nabumetone	Nabumetone	17	suppressed
Tradjenta	Linagliptin	17	suppressed
Azithromycin	Azithromycin	16	16
Fluticasone Propionate	Fluticasone Propionate	16	suppressed
Humulin R	Insulin Regular, Human	16	suppressed
Naproxen	Naproxen	16	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	16	suppressed
Chlorthalidone	Chlorthalidone	15	suppressed
Duloxetine Hcl	Duloxetine Hcl	15	suppressed
Lactulose	Lactulose	15	suppressed
Paroxetine Hcl	Paroxetine Hcl	15	suppressed
Ropinirole Hcl	Ropinirole Hcl	15	suppressed
Sertraline Hcl	Sertraline Hcl	15	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	14	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	14	suppressed
Metoprolol Succinate	Metoprolol Succinate	13	suppressed
Asa-Butalb-Caffeine-Codeine	Codeine/Butalbital/Asa/Caffein	12	suppressed
Breyna	Budesonide/Formoterol Fumarate	12	suppressed
Varenicline Tartrate	Varenicline Tartrate	12	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	11	11
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	11	suppressed
Benazepril Hcl	Benazepril Hcl	11	suppressed
Fluconazole	Fluconazole	11	suppressed
Memantine Hcl	Memantine Hcl	11	suppressed
Temazepam	Temazepam	11	suppressed
Victoza 3-Pak	Liraglutide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error